On 22 February 2018, orphan designation (EU/3/18/1972) was granted by the European Commission to CATS Consultants GmbH, Germany, for 1-[[[4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yl]oxy]methyl]cyclopropanamine-dihydrochloride (also known as AL3818 and anlotinib) for the treatment of soft tissue sarcoma.
EU/3/18/1972: Public summary of opinion on orphan designation: 1-[[[4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yl]oxy]methyl]cyclopropanamine-dihydrochloride for the treatment of soft tissue sarcoma (PDF/124.71 KB)
First published: 11/04/2018
Last updated: 11/04/2018
|Disease / condition||
Treatment of soft tissue sarcoma
|Date of decision||
|Orphan decision number||
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.